Japanese pharma major Daiichi Sankyo (TYO: 4568) has announced a raft of structural changes affecting its corporate activities, research and development (R&D) and biologics-related functions.
The company has decided in recent months to close research subsidiaries based in Japan and India, and now it has given details on wider organizational changes which will take affect from April 1.
Where its corporate activities are concerned, the company is making changes to advance the Daiichi Sankyo Cancer Enterprise and strengthen its product portfolio management, and to push forward the execution of the group’s five-year business plan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze